Transdermal estradiol and oral or vaginal natural progesterone: Bleeding patterns

Climacteric

Volumn 13, Issue 5, 2010, Pages 442-446

  Di Carlo, C ^a   Tommaselli, G A ^a   Gargano, V ^a   Savoia, F ^a   Bifulco, G ^a   Nappi, C ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

endometrium; Hormone replacement therapy; natural progesterone; vaginal bleeding; vaginal progesterone

Indexed keywords

DERMESTRIL 50; ESTRADIOL; PROGESTERONE; UNCLASSIFIED DRUG;

ADULT; AMENORRHEA; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; ENDOMETRIUM; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL IRREGULARITY; MULTIPLE CYCLE TREATMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SPOTTING; THICKNESS; UTERINE BLEEDING PATTERN;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE; PROSPECTIVE STUDIES; UTERINE HEMORRHAGE;

EID: 77956139922     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2010.490605     Document Type: Article

References (12)

1. de Ligniè res B. Oral micronized progesterone. Clin Ther 1999; 21:41-60.
2. Wiegratz I, Kuhl H. Progestogen therapies: differences in clinical effects? Trends Endocrinol Metab 2004;15:277-285
3. Benagiano G, Primiero FM, Farris M. Clinical profile of contraceptive progestins. Eur J Contracept Reprod Health Care 2004;9:182-193
4. Hargrove JT, Maxson WS, Wentz AC. Absorption of oral progesterone is influenced by vehicle and particle size. Am J Obstet Gynecol 1989;161:948-951
5. Ottosson UB, Carlstrom K, Damber JE, von Schoultz B. Serum levels of progesterone and some of its metabolites including deoxycorticosterone after oral and parenteral administration. Br J Obstet Gynaecol 1984;91:1111-1119
6. de Ligniè res B, Dennerstein L, Backstrom T. Influence of route of administration on progesterone metabolism. Maturitas 1995;21:251-257
7. Grady D, Emster VL. Hormone replacement therapy and endometrial cancer: are current regimens safe? J Natl Cancer Inst 1997;98:1088-1089
8. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273:199-208.
9. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448-454
10. Di Carlo C, Sammartino A, Di Spiezio Sardo A, et al. Bleeding patterns during continuous estradiol with different sequential progestogens therapy. Menopause 2005; 12:520-525
11. Affinito P, Palomba S, Sammartino A, Bonifacio M, Nappi C. Ultrasonographic endometrial monitoring during continuous-sequential hormonal replacement therapy regimen in postmenopausal women. Maturitas 2001;39: 239-244
12. Cicinelli E, Cignarelli M, Sabatelli S, et al. Plasma concentrations of progesterone are higher in the uterine artery than in the radial artery after vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. Fertil Steril 1998;69: 471-3